Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overweight Subjects Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

NCT01648296
View directory record Official record
Conditions
Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
Interventions
[18F]FluorbetaOx
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug

NCT00644839
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

NCT00747929
View directory record Official record
Conditions
Obesity
Interventions
S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
724 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

NCT02235961
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

NCT05064735
View directory record Official record
Conditions
Obesity
Interventions
semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
61
States / cities
Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

NCT03486392
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Liraglutide, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 14, 2026, 4:26 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00495014
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GSK376501, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

NCT00297180
View directory record Official record
Conditions
Obesity
Interventions
GW869682
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
3
States / cities
Daytona Beach, Florida • Baton Rouge, Louisiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

NCT00748605
View directory record Official record
Conditions
Obesity
Interventions
S-2367 Placebo, S-2367 1600 mg q.d. 54 Weeks, S-2367 1600 mg q.d. 60 weeks, LCD (low calorie diet), RCD (reduced calorie diet)
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126
View directory record Official record
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects

NCT02818699
View directory record Official record
Conditions
Overweight, Obese
Interventions
Placebo, EMIQ
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Oral Glucosamine on Insulin and Blood Vessel Activity in Normal and Obese People

NCT00065377
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Glucosamine Hydrochloride
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2006 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 2Phase 3 Interventional

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

NCT00134199
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598, sibutramine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
15
States / cities
Clearwater, Florida • Kissimmee, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Sep 14, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 14, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

NCT00367783
View directory record Official record
Conditions
Obesity
Interventions
CP-741,952
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2011 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

NCT03757130
View directory record Official record
Conditions
Obesity
Interventions
AMG 598, Placebo, Liraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Changes in Gut Hormones, Body Composition and Energy Expenditure After Roux-en-Y

NCT02048501
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Resting Metabolic Rate (RMR), Duel-energy x-ray absorptiometry (DEXA), Visual Analog Scale (VAS), Meal Stimulation Test
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fructose-Induced Palmitate Synthesis in Overweight Subjects

NCT00535535
View directory record Official record
Conditions
Elevated Triglycerides, Diabetes, Cardiovascular Disease
Interventions
Fructose, Fructose and Glucose
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 14, 2026, 4:26 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

NCT06745284
View directory record Official record
Conditions
Obesity
Interventions
Survodutide, Semaglutide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 14, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

NCT00645463
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Sep 14, 2026, 4:26 AM EDT